Meta tyrosine derivatives as rho-kinase inhibitors
US11725007B2 · kind B2 · utility
0Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 12, 2018 |
| Grant date | Aug 15, 2023 |
| Priority date | — |
| Expiry date | Jul 1, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P11/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to compounds of formula (I) inhibiting Rho Kinase that are meta tyrosine derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.